Agnieszka K. Witkiewicz

Dermatology

328 Elm St
Buffalo, NY 14263

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 125 publications

Increasing Use of Germline Genetic Testing in Pancreatic Ductal Adenocarcinoma and Relationship to Clinical Outcome: A Single-Institution Study.

Increasing Use of Germline Genetic Testing in Pancreatic Ductal Adenocarcinoma and Relationship to Clinical Outcome: A Single-Institution Study.

Journal: JCO precision oncology

Published: April 16, 2026

Targeting Distinct Cell Cycle Nodes Overcomes KRAS/RAS Inhibitor Resistance.

Targeting Distinct Cell Cycle Nodes Overcomes KRAS/RAS Inhibitor Resistance.

Journal: bioRxiv : the preprint server for biology

Published: April 10, 2026

The evolving landscape of CDK inhibitor use in breast cancer therapy and beyond.

The evolving landscape of CDK inhibitor use in breast cancer therapy and beyond.

Journal: Nature reviews. Drug discovery

Published: March 25, 2026

Real-World Plasma Thymidine Kinase Activity in High-Risk and Metastatic Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Treated With Cyclin-Dependent Kinase 4/6 Inhibitors.

Real-World Plasma Thymidine Kinase Activity in High-Risk and Metastatic Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Treated With Cyclin-Dependent Kinase 4/6 Inhibitors.

Journal: JCO precision oncology

Published: January 23, 2026

p16 expression confers sensitivity to CDK2 inhibitors in cyclin E1-driven ovarian cancers.

p16 expression confers sensitivity to CDK2 inhibitors in cyclin E1-driven ovarian cancers.

Journal: Science signaling

Published: November 25, 2025

HNF1A is a novel BRD4 target and critical for BET-inhibitor response in pancreatic ductal adenocarcinoma.

HNF1A is a novel BRD4 target and critical for BET-inhibitor response in pancreatic ductal adenocarcinoma.

Journal: bioRxiv : the preprint server for biology

Published: November 19, 2025

Clinical and Molecular Evaluation of HER2-Low and HER2-Ultralow Breast Cancer in the Penelope-B Clinical Trial Cohort.

Clinical and Molecular Evaluation of HER2-Low and HER2-Ultralow Breast Cancer in the Penelope-B Clinical Trial Cohort.

Journal: Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc

Published: November 05, 2025

Cell Cycle Plasticity and Heterogeneity: An Underappreciated Feature of Cancer and Treatment Response.

Cell Cycle Plasticity and Heterogeneity: An Underappreciated Feature of Cancer and Treatment Response.

Journal: Cancer heterogeneity and plasticity

Published: October 17, 2025

Cyclin E modulates vulnerability to CDC7 kinase inhibition.

Cyclin E modulates vulnerability to CDC7 kinase inhibition.

Journal: Oncogenesis

Published: October 07, 2025

Reply to: Germline and Somatic BRCA1/2 Mutations in Breast Cancer Treatment Strategies.

Reply to: Germline and Somatic BRCA1/2 Mutations in Breast Cancer Treatment Strategies.

Journal: JCO precision oncology

Published: September 02, 2025

TP53 mutation is associated with improved disease control in patients with advanced RAS wild-type colorectal adenocarcinoma treated with cetuximab and pembrolizumab.

TP53 mutation is associated with improved disease control in patients with advanced RAS wild-type colorectal adenocarcinoma treated with cetuximab and pembrolizumab.

Journal: International journal of cancer

Published: July 17, 2025

RB loss sensitizes triple-negative breast cancer to apoptosis induced by cellular stress.

RB loss sensitizes triple-negative breast cancer to apoptosis induced by cellular stress.

Journal: Cell death discovery

Published: June 08, 2025

Showing 1-12 of 125

Last Updated: 09/26/2026